Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study

Abstract Apatinib is a novel antiangiogenic agent that targets vascular endothelial growth factor 2. The aim of our study was to explore the efficacy and safety of apatinib in the treatment of patients with recurrence or metastasis (R/M) inoperable head and neck squamous cell carcinoma (HNSCC). This...

Full description

Bibliographic Details
Main Authors: Zijing Liu, Zhuangzhuang Zheng, Lihua Dong, Xiao Guo, Xiaojing Jia, Jianfeng Wang, Lingbin Meng, Xiangyan Cui, Xin Jiang
Format: Article
Language:English
Published: Nature Portfolio 2022-10-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-20272-x